TG Therapeutics schedules Q2 2026 earnings call for August 3, with CEO Michael Weiss leading.

TG Therapeutics announced a conference call on August 3, 2026, at 8:30 AM ET to discuss its second quarter 2026 financial results and business outlook. CEO Michael S. Weiss will host the call, which investors can join via phone or webcast on the company's website. The company will release its financial results in a press release before the call. TG Therapeutics focuses on developing treatments for B-cell diseases and has FDA approval for BRIUMVI® to treat multiple sclerosis.